BeOne Medicines AG earns Strong Buy rating as BRUKINSA drives growth and pipeline advances. Click here to find out why ONC ...
ITM-11 significantly improved PFS and OS compared to everolimus in GEP-NET patients, meeting primary and secondary endpoints. Subgroup analyses showed ITM-11's efficacy across tumor grades and prior ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback